Novo Nordisk Inc. et al v. Teva Pharmaceuticals USA, Inc.
| Novo Nordisk Inc. and Novo Nordisk A/S |
| Teva Pharmaceuticals USA, Inc. |
| 1:2017cv00227 |
| March 3, 2017 |
| US District Court for the District of Delaware |
| Wilmington Office |
| New Castle |
| Vacant Judgeship (2017) |
| Mary Pat Thynge |
| Patent |
| 35 U.S.C. ยง 271 |
| None |
Follow case documents by RSS
Available Case Documents
The following documents for this case are available for you to view or download:
| Document Text |
|---|
Filing
68
ORDER ADOPTING REPORT AND RECOMMENDATIONS re 61 Report and Recommendations. Signed by Judge Joseph F. Bataillon on 8/8/2018. (crb)
|
|
Filing
61
REPORT AND RECOMMENDATIONS re: Claim Construction. Please note that when filing Objections pursuant to Federal Rule of Civil Procedure 72(b)(2), briefing consists solely of the Objections (no longer than ten (10) pages) and the Response to the Objections (no longer than ten (10) pages). No further briefing shall be permitted with respect to objections without leave of the Court. Objections to R&R due by 7/10/2018. Signed by Judge Mary Pat Thynge on 6/26/2018. (fms)
|
Use the links below to access additional information about this case on the US Court's PACER system. A subscription to PACER is required.
Access this case on the Delaware District Court's Electronic Court Filings (ECF) System
- Search for Party Aliases
- Associated Cases
- Attorneys
- Case File Location
- Case Summary
- Docket Report
- History/Documents
- Parties
- Related Transactions
- Check Status
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
